Skip to main content
SpringerPlus
Fig. 4 | SpringerPlus

Fig. 4

From: The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study

Fig. 4

Neutropenic events versus supportive measures in subgroup of patients with planned RDI ≥85% and no primary prophylaxis with colony-stimulating factors. Among 729 patients in this subgroup 29 had unknown hormone receptors status and 3 had unknown menopausal status. ER estrogen receptor, PR progesterone receptor, RDI relative dose intensity, 1+ cycle at least one cycle.

Back to article page